Broadly, these findings suggest that the impact of tau pathology on brain atrophy may be underway even at subthreshold accumulation of Aβ, raising the possibility that early anti-tau interventions may have greater therapeutic potential than anti-Aβ, especially early in the course of disease. Here, MAPT is linked to Brain atrophy.